NUK - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • What will the cardiovascula...
    Collins, Brendan; Bandosz, Piotr; Guzman-Castillo, Maria; Pearson-Stuttard, Jonathan; Stoye, George; McCauley, Jeremy; Ahmadi-Abhari, Sara; Araghi, Marzieh; Shipley, Martin J; Capewell, Simon; French, Eric; Brunner, Eric J; O'Flaherty, Martin

    PloS one, 06/2022, Letnik: 17, Številka: 6
    Journal Article

    There is uncertainty around the health impact and economic costs of the recent slowing of the historical decline in cardiovascular disease (CVD) incidence and the future impact on dementia and disability. Previously validated IMPACT Better Ageing Markov model for England and Wales, integrating English Longitudinal Study of Ageing (ELSA) data for 17,906 ELSA participants followed from 1998 to 2012, linked to NHS Hospital Episode Statistics. Counterfactual design comparing two scenarios: Scenario 1. CVD Plateau-age-specific CVD incidence remains at 2011 levels, thus continuing recent trends. Scenario 2. CVD Fall-age-specific CVD incidence goes on declining, following longer-term trends. The main outcome measures were age-related healthcare costs, social care costs, opportunity costs of informal care, and quality adjusted life years (valued at £60,000 per QALY). The total 10 year cumulative incremental net monetary cost associated with a persistent plateauing of CVD would be approximately £54 billion (95% uncertainty interval £14.3-£96.2 billion), made up of some £13 billion (£8.8-£16.7 billion) healthcare costs, £1.5 billion (-£0.9-£4.0 billion) social care costs, £8 billion (£3.4-£12.8 billion) informal care and £32 billion (£0.3-£67.6 billion) value of lost QALYs.